Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.
Limited growth with imperfect balance sheet.
Share Price & News
How has Reata Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RETA has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RETA exceeded the US Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: RETA exceeded the US Market which returned 24.7% over the past year.
Price Volatility Vs. Market
How volatile is Reata Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StOur Take On Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Salary
1 month ago | Simply Wall StCan We See Significant Insider Ownership On The Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Share Register?
2 months ago | Simply Wall StThe Reata Pharmaceuticals (NASDAQ:RETA) Share Price Is Up 736% And Shareholders Are Delighted
Is Reata Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Reata Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Reata Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of RETA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Reata Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RETA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RETA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RETA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RETA's revenue (53.1% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: RETA's revenue (53.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RETA's Return on Equity is forecast to be high in 3 years time
How has Reata Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RETA is currently unprofitable.
Growing Profit Margin: RETA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RETA is unprofitable, and losses have increased over the past 5 years at a rate of -73.3% per year.
Accelerating Growth: Unable to compare RETA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RETA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.8%).
Return on Equity
High ROE: RETA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is Reata Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RETA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: RETA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: RETA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: RETA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: RETA has a low level of unsold assets or inventory.
Debt Coverage by Assets: RETA has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RETA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RETA has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -43.2% each year.
What is Reata Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RETA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RETA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RETA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RETA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RETA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Reata Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
J. Huff (65yo)
Mr. J. Warren Huff has been the Chief Executive Officer and President of Reata Pharmaceuticals, Inc. (formerly, Reata Discovery Inc) since founding in 2002 and has been its Chairman since 2002. Mr. Huff is ...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD934.50K) is below average for companies of similar size in the US market ($USD6.46M).
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
Management Age and Tenure
Experienced Management: RETA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Age and Tenure
Experienced Board: RETA's board of directors are seasoned and experienced ( 15.1 years average tenure).
Insider Buying: RETA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Chief Executive Officer
Member of the Board of Directors
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.7%.
J. Huff (65yo)
- Tenure: 18yrs
- Compensation: US$934.50k
Mike Wortley (71yo)
Executive VP & Chief Legal Officer
- Tenure: 4.8yrs
Jason Wilson (49yo)
Executive Vice President of Operations
- Tenure: 0.4yrs
- Compensation: US$427.50k
VP of Corporate Communications & Strategy
Colin Meyer (40yo)
Chief Medical Officer & Executive VP of Product Development
- Compensation: US$625.50k
VP & Chief Accounting Officer
Manmeet Soni (41yo)
CFO & Executive VP
- Tenure: 0.4yrs
Vice President of Marketing
- Tenure: 1.6yrs
CTO & Senior VP of CMC
VP & Chief Human Resources Officer
- Tenure: 0.8yrs
J. Huff (65yo)
- Tenure: 18yrs
- Compensation: US$934.50k
William Rose (51yo)
- Tenure: 3.9yrs
- Compensation: US$263.81k
Jack Nielsen (55yo)
Lead Independent Director
- Compensation: US$298.93k
Richard McGaughy (47yo)
- Tenure: 15.1yrs
- Compensation: US$260.79k
Jim Bass (60yo)
- Tenure: 15.5yrs
- Compensation: US$267.92k
Bill McClellan (59yo)
- Tenure: 2.8yrs
- Compensation: US$292.93k
Reata Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Reata Pharmaceuticals, Inc.
- Ticker: RETA
- Exchange: NasdaqGM
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.757b
- Shares outstanding: 32.67m
- Website: https://www.reatapharma.com
Number of Employees
- Reata Pharmaceuticals, Inc.
- 5320 Legacy Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RETA||NasdaqGM (Nasdaq Global Market)||Yes||Class A Common Stock||US||USD||May 2016|
|2R3||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||May 2016|
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich’s ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/01/24 01:27|
|End of Day Share Price||2020/01/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.